Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CX-904 |
Synonyms | |
Therapy Description |
CX-904 comprises a bispecific antibody targeting both EGFR and CD3 linked to masking peptide that is cleaved by tumor-specific proteases in the tumor microenvironment, which potentially leads to an enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EGFR (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CX-904 | CX 904|CX904|AMG 651|AMG651|AMG-651 | CD3 Antibody 92 EGFR Antibody 56 | CX-904 comprises a bispecific antibody targeting both EGFR and CD3 linked to masking peptide that is cleaved by tumor-specific proteases in the tumor microenvironment, which potentially leads to an enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EGFR (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05387265 | Phase I | CX-904 | A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors | Recruiting | USA | 0 |